Evidence map›Paper›PMID 41407241›Full record

ArticleVirus research2026

Replication competent La Crosse virus pseudotyped VSV vector system as vaccine and serological diagnostic reagent.

Ianko Iankov, Arun Ammayappan, Kimberly Viker, Carla Weisend, Matthew Beard, Brandy Russell, Elitza Theel, Hideki Ebihara, Evanthia Galanis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ianko IankovDepartment of Molecular Medicine, Mayo Clinic, Rochester MN, 55905, USA; Department of Oncology, Mayo Clinic, Rochester MN, 55905, USA. Electronic address: iankov.ianko@mayo.edu.
Arun AmmayappanDepartment of Molecular Medicine, Mayo Clinic, Rochester MN, 55905, USA.
Kimberly VikerDepartment of Molecular Medicine, Mayo Clinic, Rochester MN, 55905, USA.
Carla WeisendDepartment of Molecular Medicine, Mayo Clinic, Rochester MN, 55905, USA.
Matthew BeardDepartment of Molecular Medicine, Mayo Clinic, Rochester MN, 55905, USA.
Brandy RussellDivision of Vector Borne Diseases, Centers for Disease Control and Prevention, Fort Collins CO, 80521, USA.
Elitza TheelDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN, 55905, USA.
Hideki EbiharaNational Institute of Infectious Diseases, Department of Virology I, Tokyo 162-8640, Japan.
Evanthia GalanisDepartment of Molecular Medicine, Mayo Clinic, Rochester MN, 55905, USA; Department of Oncology, Mayo Clinic, Rochester MN, 55905, USA. Electronic address: galanis.evanthia@mayo.edu.

Funding

Novel multipronged Immunovirotherapy Approach for GBM TreatmentR01CA258239 · NCI · MAYO CLINIC ROCHESTER · PI GALANIS, EVANTHIA · 2021 to 2025
$1.9M
NCI NIH HHS R01 CA258239
6 · The paper itself

Abstract

La Crosse encephalitis virus (LACV) is the second most frequently diagnosed arboviral cause of meningoencephalitis and the most common cause of pediatric viral encephalitis in the US. Multiple factors, including climate changes and invasive mosquito species adaptation contribute to the emerging spread of LACV in new areas. There is an expanding need for broader investigation on seroprevalence, development of novel antiviral drugs and vaccines for prevention of LACV infection. We pseudotyped replication-competent vesicular stomatitis virus (VSV) vectors with LACV surface glycoproteins using wild type (VSV-LACV) and attenuated (VSV-M51-LACV) backbones. Recombinant strains were tested as diagnostic tools in LACV serology and as potential live anti-LACV vaccine in vivo. The attenuated VSV-M51R-LACV vector was safe after direct intracranial inoculation in mice. Intraperitoneal immunization induced strong humoral response reaching average complete neutralization titer (VN

Indexed as

Encephalitis, CaliforniaGenetic VectorsLa Crosse virusVesicular stomatitis Indiana virusVesiculovirusViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHumansMiceMice, Inbred BALB CNeutralization TestsSerologic TestsVaccines, AttenuatedAntibodies, NeutralizingAntibodies, ViralVaccines, AttenuatedViral VaccinesDried blood spotsLa crosse encephalitis virusPseudotyped vsvSerologyVaccineVirus neutralization

Identifiers

PMID41407241
PMCPMC12811681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.